Monte Rosa Therapeutics Inc (NASDAQ: GLUE) kicked off on Monday, up 93.87% from the previous trading day, before settling in for the closing price of $4.89. Over the past 52 weeks, GLUE has traded in a range of $2.44-$8.84.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 28.94%. With a float of $44.59 million, this company’s outstanding shares have now reached $50.14 million.
Let’s determine the extent of company efficiency that accounts for 133 employees. In terms of profitability, gross margin is 47.37%, operating margin of -960.79%, and the pretax margin is -895.4%.
Monte Rosa Therapeutics Inc (GLUE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Monte Rosa Therapeutics Inc is 27.35%, while institutional ownership is 62.08%. The most recent insider transaction that took place on Oct 28 ’24, was worth 240,000. Before that another transaction happened on Sep 20 ’24, when Company’s 10% Owner sold 1,132,566 for $6.53, making the entire transaction worth $7,395,203. This insider now owns 5,099,336 shares in total.
Monte Rosa Therapeutics Inc (GLUE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 28.94% per share during the next fiscal year.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Trading Performance Indicators
Take a look at Monte Rosa Therapeutics Inc’s (GLUE) current performance indicators. Last quarter, stock had a quick ratio of 6.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 101.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.24, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.78 in one year’s time.
Technical Analysis of Monte Rosa Therapeutics Inc (GLUE)
Looking closely at Monte Rosa Therapeutics Inc (NASDAQ: GLUE), its last 5-days average volume was 19.12 million, which is a jump from its year-to-date volume of 0.69 million. As of the previous 9 days, the stock’s Stochastic %D was 29.20%. Additionally, its Average True Range was 0.88.
During the past 100 days, Monte Rosa Therapeutics Inc’s (GLUE) raw stochastic average was set at 68.23%, which indicates a significant increase from 62.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 275.44% in the past 14 days, which was higher than the 140.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.71, while its 200-day Moving Average is $5.31. However, in the short run, Monte Rosa Therapeutics Inc’s stock first resistance to watch stands at $12.54. Second resistance stands at $15.59. The third major resistance level sits at $18.79. If the price goes on to break the first support level at $6.29, it is likely to go to the next support level at $3.09. Now, if the price goes above the second support level, the third support stands at $0.04.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Key Stats
The company with the Market Capitalisation of 581.79 million has total of 50,512K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -135,350 K annual income. Company’s last quarter sales were recorded 4,700 K and last quarter income was -30,310 K.
